Migraine and Headache
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.
The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.
Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.
The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.
Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.